News Percheron Therapeutics Limited BOERSE MUENCHEN

Equities

AWY0

AU0000317281

Market Closed - BOERSE MUENCHEN Other stock markets 20:43:23 03/07/2024 BST			5-day change	1st Jan Change
0.0504 ^EUR	0.00%		+4.13%	+46.51%

06-17	Percheron Therapeutics Appoints CFO	MT
06-03	Percheron Therapeutics Names Chief Medical Advisor	MT

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Percheron Therapeutics Appoints CFO	06-17	MT
Percheron Therapeutics Names Chief Medical Advisor	06-03	MT
Percheron Therapeutics Completes Enrollment for Phase Two Muscular Dystrophy Trial; Shares Rise 3%	05-29	MT
Percheron Therapeutics Secures US Patent for Muscular Dystrophy Medicinal Candidate	05-20	MT
WHO Selects International Nonproprietary Name for Percheron Therapeutics' Drug Candidate ATL1102	05-06	MT
Percheron Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	02-28	CI
Dimerix Appoints Nonexecutive Chair	11-20	MT
Antisense Therapeutics Limited has Changed its Name to Percheron Therapeutics Limited	11-15	CI
Antisense Therapeutics Launches Share Sale Facility for Unmarketable Parcels	09/10/23	MT
Antisense Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2023	25/08/23	CI
Antisense Therapeutics' Share Purchase Plan Raises AU$3.3 Million	21/08/23	MT
Antisense Therapeutics Appoints CEO/Managing Director	07/08/23	MT
Antisense Therapeutics Limited Announces Commencement of James Garner as Chief Executive Officer, Effective 7 August 2023	06/08/23	CI
Antisense Therapeutics Limited Announces Management Changes	06/08/23	CI
Antisense Therapeutics to Launch Share Purchase Plan; Shares Plunge 8%	20/07/23	MT
Antisense Therapeutics Limited Receives MHRA Approval for ATL1102 Phase IIb DMD Clinical Trial in UK	27/06/23	CI
Antisense Therapeutics Doses First Patient in Duchenne Muscular Dystrophy Drug Trial; Shares Jump 11%	08/06/23	MT
Antisense Therapeutics Appoints CEO/Managing Director	08/05/23	MT
Antisense Therapeutics Limited Announces the Appointment of James Garner as Chief Executive Officer, Effective 07 August 2023	07/05/23	CI
Antisense Therapeutics Limited Appoints James Garner as Managing Director and to Join the Board as a Non-Executive Director	07/05/23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Percheron Therapeutics Limited BOERSE MUENCHEN

Equities

AWY0

AU0000317281

Summary

Filters